Belozersky Institute of Physico-Chemical Biology, Moscow State University, Moscow, Russian Federation.
Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, Russian Federation.
Curr Mol Pharmacol. 2019;12(3):202-214. doi: 10.2174/1874467212666181127151059.
Targeting of drugs to the subcellular compartments represents one of the modern trends in molecular pharmacology. The approach for targeting mitochondria was developed nearly 50 years ago, but only in the last decade has it started to become widely used for delivering drugs. A number of pathologies are associated with mitochondrial dysfunction, including cardiovascular, neurological, inflammatory and metabolic conditions.
This mini-review aims to highlight the role of mitochondria in pathophysiological conditions and diseases, to classify and summarize our knowledge about targeting mitochondria and to review the most important preclinical and clinical data relating to the antioxidant lipophilic cations MitoQ and SkQ1.
This is a review of available information in the PubMed and Clinical Trials databases (US National Library of Medicine) with no limiting period.
Mitochondria play an important role in the pathogenesis of many diseases and possibly in aging. Both MitoQ and SkQ1 have shown many beneficial features in animal models and in a few completed clinical trials. More clinical trials and research efforts are needed to understand the signaling pathways influenced by these compounds. The antioxidant lipophilic cations have great potential for the treatment of a wide range of pathologies.
将药物靶向到亚细胞隔室是分子药理学的现代趋势之一。靶向线粒体的方法几乎在 50 年前就已开发出来，但直到最近十年才开始广泛用于药物输送。许多病理学与线粒体功能障碍有关，包括心血管、神经、炎症和代谢疾病。
本迷你综述旨在强调线粒体在病理生理条件和疾病中的作用，对靶向线粒体进行分类和总结，并综述与抗氧化亲脂阳离子 MitoQ 和 SkQ1 相关的最重要的临床前和临床数据。
这是对 PubMed 和临床试验数据库（美国国家医学图书馆）中可用信息的综述，没有时间限制。
线粒体在许多疾病的发病机制中起着重要作用，可能在衰老中也起着重要作用。MitoQ 和 SkQ1 在动物模型和少数已完成的临床试验中都表现出了许多有益的特征。需要更多的临床试验和研究工作来了解这些化合物影响的信号通路。抗氧化亲脂阳离子具有治疗广泛病理疾病的巨大潜力。
